Table 1.
Group | n | Weight (g) | Liver (g) | Liver:BW ratio |
Visible Lesions |
|
---|---|---|---|---|---|---|
MALE (24 Wks) |
Control (C) | 9 | 35.6±0.5 | 1.81±0.05 | 0.050±0.001 | 0 |
EtOH (E) | 9 | 35.1±0.7 | 2.14±0.09 | 0.056±0.002 | 0 | |
DEN (D) | 9 | 36.9±2.4 | 2.10±0.17 | 0.057±0.002 | 0 | |
DEN+EtOH (D+E) | 14 | 34.8±0.7 | 2.08±0.12 | 0.059±0.002 | 0 | |
FEMALE (24 Wks) |
Control (C) | 10 | 25.7±0.4 | 1.30±0.03 | 0.051±0.001 | 0 |
EtOH (E) | 10 | 27.5±0.4 | 1.48±0.03 | 0.054±0.015 | 0 | |
DEN (D) | 9 | 27.9±0.6 | 1.64±0.09* | 0.059±0.003 | 0 | |
DEN+EtOH (D+E) | 14 | 25.4±0.4 | 1.35±0.03 | 0.053±0.006 | 0 | |
Group | n | Weight (g) | Liver (g) |
Liver:BW
ratio |
Visible
Lesions |
|
MALE (48 Wks) |
Control (C) | 9 | 41.2±1.0 | 1.93±0.05 | 0.047±0.001 | 0 |
EtOH (E) | 9 | 42.1±0.8 | 2.19±0.06 | 0.054±0.001 | 0 | |
DEN (D) | 8 | 36.3±2.3# | 2.59±0.35# | 0.070±0.007# | 87.5% (7/8) |
|
DEN+EtOH (D+E) | 14 | 34.7±0.7# | 4.44±0.16* | 0.129±0.006* | 93.7% (13/14) |
|
FEMALE (48 Wks) |
Control (C) | 10 | 27.9±0.6 | 1.37±0.05 | 0.049±0.001 | 0 |
EtOH (E) | 10 | 28.6±0.5 | 1.41±0.04 | 0.049±0.001 | 0 | |
DEN (D) | 9 | 28.2±0.8 | 1.78±0.14* | 0.063±0.005* | 44.4% (4/9) |
|
DEN+EtOH (D+E) | 14 | 25.7±1.1* | 1.31±0.07 | 0.050±0.001 | 35.7% (5/14) |
p<0.05 versus all other treatments groups within male or females assayed at matching time points (24 or 48 weeks).
p<0.05 versus C or E within male or female groups assayed at matching time points.